The development of biomarkers in CSF is gaining momentum for the early detection of AD due to its hallmark characteristics, including disruptions in APP processing, activation of the amyloidogenic pathway, and Aβ42 accumulation. This evidence concerns the gene APP and Alzheimer disease.